Primary Hyperoxaluria Type 1 Treatments
Find Primary Hyperoxaluria Type 1 Treatments
Brand Name
Oxlumo
Generic Name
Lumasiran
View Brand Information FDA approval date: November 23, 2020
Form: Injection
What is Oxlumo (Lumasiran)?
OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 to lower urinary and plasma oxalate levels in pediatric and adult patients [see Clinical Pharmacology (1.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France - DAILY-LUMA
Summary: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by mutation in the AGXT gene encoding the hepatic peroxisomal enzyme AGT. Reduced AGT activity results in increased glyoxylate and oxalate production, causing the formation of kidney stones, nephrocalcinosis and renal failure. Clinical trials of Lumasiran have provided information on the efficacy and safety of Lumasiran in the tre...
